Management of Alzheimer disease;Prise en charge de la maladie d'Alzheimer

Presse Medicale

Volumn 36, Issue 10 II, 2007, Pages 1500-1510

  Belmin, Joël ^a   Péquignot, Renaud ^a   Konrat, Cécile ^a   Pariel Madjlessi, Sylvie ^a  

^a HÔPITAL CHARLES FOIX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ARIPIPRAZOLE; CITALOPRAM; CLOMIPRAMINE; DONEPEZIL; FLUOXETINE; GALANTAMINE; HALOPERIDOL; IMIPRAMINE; MEMANTINE; OLANZAPINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; ZOLPIDEM TARTRATE; AMINO ACID RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE; PSYCHOTROPIC AGENT;

ALZHEIMER DISEASE; CASE MANAGEMENT; DRUG EFFICACY; DRUG TOLERABILITY; EDUCATION PROGRAM; HUMAN; OCCUPATIONAL THERAPY; SHORT SURVEY; TREATMENT INDICATION; AGED; ANIMAL; CAREGIVER; COMPARATIVE STUDY; DISEASE MODEL; EDUCATION; FOLLOW UP; FORECASTING; HEALTH EDUCATION; MENTAL DISEASE; META ANALYSIS; NURSING; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TIME;

AGED; ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; CAREGIVERS; CASE MANAGEMENT; CHOLINESTERASE INHIBITORS; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; FOLLOW-UP STUDIES; FORECASTING; HEALTH EDUCATION; HUMANS; INDANS; MEMANTINE; MENTAL DISORDERS; META-ANALYSIS AS TOPIC; NOOTROPIC AGENTS; OCCUPATIONAL THERAPY; PIPERIDINES; PRACTICE GUIDELINES AS TOPIC; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 34848911642     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2007.04.028     Document Type: Short Survey

References (49)

1. Office parlementaire d'évaluation des politiques de santé. La prise en charge de la maladie d'Alzheimer et des maladies apparentées. Rapport de Cécile Gallez 2005 (n° 2454/466). Paris : Assemblée Nationale ; 2005.
2. Klafki H.W., Staufenbiel M., Kornhuber J., and Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 129 (2006) 2840-2855
3. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1 (2006) (CD005593)
4. Birks J., and Harvey R.J. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 1 (2006) (CD001190)
5. Loy C., and Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 1 (2006) (CD001747)
6. Seltzer B. Donepezil: a review. Expert Opin Drug Metab Toxicol. 1 (2005) 527-536
7. Loy C., and Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 1 (2006) (CD001747)
8. National Institute for Health and Clinical Excellence. Final Appraisal Determination: Alzheimer's disease - donepezil, galantamine, rivastigmine (review) & memantine; 2006 pp 1-63. URL: http://www.nice.org.uk/download.aspx?o=322952 (consulté le 1/3/2007).
9. Blennow K., de Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet 368 (2006) 387-403
10. Winblad B., Kilander L., Eriksson S., Minthon L., Batsman S., Wetterholm A.L., et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 367 (2006) 1057-1065
11. Wilcock G., Howe I., Coles H., Lilienfeld S., Truyen L., Zhu Y., et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging 20 (2003) 777-789
12. Bullock R., Touchon J., Bergman H., Gambina G., He Y., Rapatz G., et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 21 (2005) 1317-1327
13. Robinson D.M., and Keating G.M. Memantine: a review of its use in Alzheimer's disease. Drugs 66 (2006) 1515-1534
14. McShane R., Areosa Sastre A., and Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2 (2006) (CD003154)
15. Peskind E.R., Potkin S.G., Pomara N., Ott B.R., Graham S.M., Olin J.T., et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 14 (2006) 704-715
16. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., Gergel I., and Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 (2004) 317-324
17. Lyketsos C.G., DelCampo L., Steinberg M., Miles Q., Steele C.D., Munro C., et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 60 (2003) 737-746
18. Magai C., Kennedy G., Cohen C.I., and Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry 8 (2000) 66-74
19. Petracca G.M., Chemerinski E., and Starkstein S.E. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 13 (2001) 233-240
20. Teri L., Reifler B.V., Veith R.C., Barnes R., White E., McLean P., et al. Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. J Gerontol 46 (1991) 372-377
21. Petracca G., Teson A., Chemerinski E., Leiguarda R., and Starkstein S.E. A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 8 (1996) 270-275
22. Taragano F.E., Lyketsos C.G., Mangone C.A., Allegri R.F., and Comesana-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 38 (1997) 246-252
23. Pollock B.G., Mulsant B.H., Rosen J., Sweet R.A., Mazumdar S., Bharucha A., et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 159 (2002) 460-465
24. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 170 (2004) 1395
25. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 167 (2002) 1269-1270
26. Schneider L.S., Dagerman K.S., and Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294 (2005) 1934-1943
27. Schneider L.S., Dagerman K., and Insel P.S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14 (2006) 191-210
28. Wang P.S., Schneeweiss S., Avorn J., Fischer M.A., Mogun H., Solomon D.H., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353 (2005) 2335-2341
29. Lonergan E., Luxenberg J., and Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2 (2002) (CD002852)
30. Ballard C., and Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 7 (2006) 492-500
31. Ballard C., and Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 1 (2006) (CD003476)
32. Schneider L.S., Tariot P.N., Dagerman K.S., Davis S.M., Hsiao J.K., Ismail M.S., et al., CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355 (2006) 1525-1538
33. Tariot P.N., Schneider L., Katz I.R., Mintzer J.E., Street J., Copenhaver M., et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 14 (2006) 767-776
34. Lonergan E.T., Cameron M., and Luxenberg J. Valproic acid for agitation in dementia. Cochrane Database Syst Rev 2 (2004) (CD003945)
35. Tariot P.N., Raman R., Jakimovich L., Schneider L., Porsteinsson A., Thomas R., et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry 13 (2005) 942-949
36. Agence d'accréditation et d'évaluation en santé (ANAES). Prise en charge non médicamenteuse de la maladie d'Alzheimer et des troubles apparentés. Rapport, avril 2003. Disponible sur internet. URL : http://www.has-sante.fr/portail/upload/docs/application/pdf/Alzheimer_te chno.pdf.Consulté le 27/03/2007.
37. Callahan C.M., Boustani M.A., Unverzagt F.W., Austrom M.G., Damush T.M., Perkins A.J., et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA 295 (2006) 2148-2157
38. Shelton P., Schraeder C., Dworak D., Fraser C., and Sager M.A. Caregivers' utilization of health services: results from the Medicare Alzheimer's Disease Demonstration, Illinois Site. J Am Geriatr Soc 49 (2001) 1600-1605
39. Graff M.J.L., Vermooij-Dassen M.J.M., Thijssen M., Dekker J., Hoefnagels W.H.L., and Rikkert M.G.M. Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial. BMJ 333 (2006) 1196-1202
40. Forbes D., Morgan D.G., Bangma J., Peacock S., and Adamson J. Light therapy for managing sleep, behaviour, and mood disturbances in dementia. Cochrane Database Syst Rev 2 (2004) (CD003946)
41. Egan M., Hobson S., and Fearing V.G. Dementia and occupation: a review of the literature. Can J Occup Ther 73 (2006) 132-140
42. Sorensen S., Pinquart M., and Duberstein P. How effective are interventions with caregivers? An updated meta-analysis. Gerontologist 42 (2002) 356-372
43. Brodaty H., Green A., and Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc 51 (2003) 657-664
44. Mittelman M.S., Ferris S.H., Shulman E., Steinberg G., and Levin B. A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA 276 (1996) 1725-1731
45. Mittelman M.S., Halley W.E., Clay O.J., and Roth D.L. Improving caregiver well-being delays nursing home placement in patients with Alzheimer's disease. Neurology 67 (2006) 1592-1599
46. Teri L., Gibbons L.E., McCurry S.M., Logsdon R.G., Buchner D.M., Barlow W.E., et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 290 (2003) 2015-2022
47. Schenk D.B., Seubert P., Grundman M., and Black R. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. Neurodegener Dis. 2 (2005) 255-260
48. Cummings J.L. Alzheimer's disease. N Engl J Med 351 (2004) 56-67
49. Dorenlot P. Démence et interventions non médicamenteuses : revue critique, bilan et perspectives. Psychol Neuropsychiatr Vieil 4 (2006) 135-144